# Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis

> **NCT00770913** · PHASE2,PHASE3 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 337 (actual)

## Conditions studied

- Refractory Reflux Esophagitis

## Interventions

- **DRUG:** E3810
- **DRUG:** E3810
- **DRUG:** E3810

## Key facts

- **NCT ID:** NCT00770913
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-11
- **Final completion:** 2010-03
- **Target enrollment:** 337 (ACTUAL)
- **Last updated:** 2012-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00770913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00770913, "Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00770913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*